Professor Jean-Claude Tardif (Montreal Heart Institute Research Centre and Professor of Medicine, University of Montreal, Montreal, Quebec, Canada) discusses the aims, rationale and recently released results of the COMMANDER-HF trial.
Filmed at ESC 2018, Munich.
View more content here.
Speaker Disclosure: Professor Jean-Claude Tardif has the following disclosures in relation to this video interview: grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, Pfizer, Sanofi and Servier. Honoraria from DalCor, Pfizer, Sanofi, Servier. Minor equity interest in DalCor.
Questions:
1. Please describe the key aims of the COMMANDER-HF trial of rivaroxaban? (0:08)
2. What do we already know about the efficacy and safety of rivaroxaban and what was the rationale behind the COMMANDER-HF trial? (1:05)
3. Which patient groups were eligible for inclusion in the COMMANDER-HF trial? (2:28)
4. What separates the COMMANDER-HF trial from previous trials of oral anticoagulants in heart failure? (3:01)
5. What were the lessons from the COMMANDER-HF trial? (3:39)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.
